Insmed Inc INSM

Healthcare Biotechnology

Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

NDAQ:INSM - Post by User

Insmed Inc

Bullboard Posts

Post by queueon Apr 20, 2004 10:04am

505 Views

Post# 7376439

Changewave Target $30

Toby’s book, ChangeWave Investing: Picking the Next Monster Stocks of the New Economy, was prominently featured on the New York Times, Wall Street Journal and USA Today bestseller lists. His long-anticipated sequel, ChangeWave Investing 2.0, debuted as the #1 selling business book on Amazon.com and was a Wall Street Journal bestseller. https://www.changewave.com/about/tobin.html

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity